NeoGenomics, Inc.

NASDAQ:NEO

Medical - Diagnostics & Research

Healthcare
$15.29 +6.03%

+$0.63 today

Market cap
$1.99B
Beta
1.81
P/E (TTM)
-2.9
EPS (TTM)
-$3.84
52W Low $4.72High $13.74

Volume 1.09M

Average 1.94M

NEO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

NeoGenomics, Inc.NASDAQ: NEO

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of $10.76M rose 19.3% year over year, ahead of the +9.5% change in trailing-twelve-month research & development. Sequentially, it rose 12.9% from the prior quarter. Over 3 fiscal years it compounded at +6.9% a year.

Context

  • Research & development amounted to 5.1% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +19.3% holds above the trailing-twelve-month pace of +9.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$10.76M+12.9% QoQ
Last fiscal yearDec 2025
$37.08M+19.0% YoY
LTMJun 2026
$38.17M+9.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+19.3%——
1 year+19.0%——
3-year CAGR+6.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
37.08M USD
Year-over-year change
+19.0%
4-year CAGR
+14.1%

Research & Development vs competitors

How NEO compares with its peers on the latest reported figures

  • NEO's LTM Jun 2026 research & development of $38.17M is the 8th highest of the 10 companies compared; the peer median is $83.32M.
  • Its year-over-year change of +9.5% is the 5th highest of 10, against a peer median of +7.6%.
  • Research & development amounts to 5.0% of revenue for NEO, versus a peer median of 16.6%.
NEO Competitors Peer median
Research & Development for NEO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GHGuardant Health, Inc.LTM Sep 2026$386.67M +7.6%-0.9%30.2%
GRALGRAIL, Inc.LTM Jun 2026$190.99M -15.8%-15.9%115.6%
MYGNMyriad Genetics, Inc.LTM Mar 2026$106.4M -7.7%+7.7%12.8%
VCYTVeracyte, Inc.LTM Jun 2026$93.37M +31.8%+20.4%16.6%
WGSGeneDx Holdings Corp.LTM Jun 2026$83.32M +64.3%-5.8%18.3%
CSTLCastle Biosciences, Inc.LTM Mar 2026$53.69M +5.8%+4.9%15.8%
PSNLPersonalis, Inc.LTM Mar 2026$52.16M +6.9%-8.2%80.9%
NEONeoGenomics, Inc.LTM Jun 2026$38.17M +9.5%+6.9%5.0%
BDSXBiodesix, Inc.LTM Mar 2026$12.42M +19.5%-2.9%12.9%
XGNExagen Inc.LTM Mar 2026$6.52M +16.5%-14.1%9.5%
FRNMFreenome, Inc. Common stock—— ———
Peer median (excluding NEO) $83.32M+7.6%-2.9%16.6%

Competitors are the stored peer set for NEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue484.33M509.73M591.64M660.57M727.33M
Cost of Revenue297.27M321.83M347.04M370.47M444.79M
Gross Profit187.06M187.9M244.6M290.1M282.54M
Gross Margin38.6%36.9%41.3%43.9%38.8%
Research & Development21.87M30.33M27.31M31.16M37.08M
Selling, General & Admin283.94M277.91M279.96M310.49M365.34M
Operating Expenses305.81M345.52M352.34M382.21M348.62M
Depreciation & Amortization53.35M69.43M72.58M72.55M67.82M
EBITDA46.5M(82.33M)(17.61M)(1.51M)(38.69M)
EBITDA Margin9.6%-16.2%-3.0%-0.2%-5.3%
Operating Income(118.75M)(157.62M)(107.74M)(92.11M)(66.08M)
Operating Margin-24.5%-30.9%-18.2%-13.9%-9.1%
Interest Income3.14M6.08M16.9M18.43M9.07M
Interest Expense8.22M7.58M6.91M6.62M3.75M
Other Income / Expenses103.68M(1.72M)10.64M11.43M(44.19M)
Income Before Tax(15.08M)(159.34M)(97.1M)(80.68M)(110.27M)
Pre-Tax Margin-3.1%-31.3%-16.4%-12.2%-15.2%
Income Tax Expense(6.73M)(15.09M)(9.13M)(1.95M)(2.24M)
Net Income(8.35M)(144.25M)(87.97M)(78.73M)(108.03M)
Net Margin-1.7%-28.3%-14.9%-11.9%-14.9%
EPS (Basic)(0.07)(1.16)(0.70)(0.62)(0.84)
EPS (Diluted)(0.07)(1.16)(0.70)(0.62)(0.84)
Weighted Avg Shares119.96M124.22M125.5M126.66M128.1M
Weighted Avg Shares (Diluted)119.96M124.22M125.5M126.66M128.1M

NeoGenomics, Inc.

NASDAQ:NEO

Intrinsic Alpha fair value

Locked

Current Price

$15.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.